A highly antigenic fragment within the zoonotic Cryptosporidium parvum Gp900 glycoprotein (Domain 3) is absent in human restricted Cryptosporidium species.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
12
2022
accepted:
16
06
2023
medline:
21
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
We identified a fragment (Domain 3-D3) of the immunodominant sporozoite surface glycoprotein of the zoonotic parasite Cryptosporidium gp900, which is absent C. hominis and C. parvum anthroponosum. The fragment is highly antigenic and is able to effectively differentiate between zoonotic C. parvum and species/genotypes that infect preferentially humans. D3 detection provides a serological tool to determine whether the source of human cryptosporidiosis is of animal or human origin. We demonstrate this in experimentally challenged piglets, mice, rats, and alpaca. We speculate that the absence of this fragment from the C. hominis and C. parvum anthroponosum gp900 protein may play a key role in their host restriction.
Identifiants
pubmed: 37590269
doi: 10.1371/journal.pone.0287997
pii: PONE-D-22-33406
pmc: PMC10434960
doi:
Substances chimiques
Glycoproteins
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0287997Subventions
Organisme : NIAID NIH HHS
ID : U19 AI109776
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI149046
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144521
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI154026
Pays : United States
Informations de copyright
Copyright: © 2023 Dayao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Parasitol. 2001 Dec;87(6):1415-22
pubmed: 11780831
Infect Immun. 2022 Jul 21;90(7):e0012722
pubmed: 35735982
BMJ. 1993 Aug 14;307(6901):417-20
pubmed: 8374453
Int J Parasitol. 2021 Aug;51(9):761-775
pubmed: 33774040
Hum Vaccin Immunother. 2019;15(6):1445-1452
pubmed: 30036127
Am J Trop Med Hyg. 2003 Jun;68(6):710-5
pubmed: 12887032
Clin Infect Dis. 2012 Dec;55 Suppl 4:S215-24
pubmed: 23169934
Infect Immun. 2000 Sep;68(9):5167-75
pubmed: 10948140
Infect Immun. 2000 Jul;68(7):4117-34
pubmed: 10858229
J Infect Dis. 2018 Jun 20;218(2):259-264
pubmed: 29514308
PLoS Negl Trop Dis. 2016 May 24;10(5):e0004729
pubmed: 27219054
Infect Immun. 2002 Oct;70(10):5670-5
pubmed: 12228296
Int J Parasitol. 2012 Jun;42(7):675-82
pubmed: 22633952
Nature. 2004 Oct 28;431(7012):1107-12
pubmed: 15510150
Infect Genet Evol. 2012 Aug;12(6):1213-21
pubmed: 22522000
J Infect Dis. 2012 Mar 15;205(6):1019-23
pubmed: 22279124
Mol Ecol. 2023 May;32(10):2633-2645
pubmed: 35652748
Nat Microbiol. 2019 May;4(5):826-836
pubmed: 30833731
Mol Biochem Parasitol. 1998 Oct 30;96(1-2):93-110
pubmed: 9851610
Am J Clin Nutr. 1997 Jan;65(1):149-52
pubmed: 8988927
Mol Biochem Parasitol. 2008 Jun;159(2):138-41
pubmed: 18400317
Am J Trop Med Hyg. 2006 Nov;75(5):851-7
pubmed: 17123976
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
Emerg Infect Dis. 2014 Feb;20(2):217-24
pubmed: 24447504
Microbes Infect. 2018 Apr;20(4):267-270
pubmed: 29357304
Clin Microbiol Rev. 2004 Jan;17(1):72-97
pubmed: 14726456
Exp Parasitol. 2012 Mar;130(3):274-81
pubmed: 21803038
Vet Parasitol. 2008 Oct 1;156(3-4):191-8
pubmed: 18583057
Int J Parasitol. 2020 Jan;50(1):19-22
pubmed: 31759945
Epidemiol Infect. 2009 Dec;137(12):1800-8
pubmed: 19527551